Craft

Horizon Therapeutics

Revenue

$3.6 B

FY, 2022

Horizon Therapeutics Summary

Company Summary

Overview
Horizon Therapeutics (formerly known as Horizon Pharma) is a biopharmaceutical company focused on researching, developing, and commercializing medicines. It offers products to treat rare, autoimmune, and inflammatory diseases. Its products include TEPEZZA, KRYSTEXXA, RAVICTI, PROCYSBI, UPLIZNA, ACTIMMUNE, etc. The company also provides patient advocacy, disease education, and patient support programs.
Type
Subsidiary
Status
Active
Founded
2008
HQ
Dublin, IE | view all locations
Website
https://www.horizontherapeutics.com/
Cybersecurity rating
ESG rating
40-49 out of 100|View all ESG data
Sectors

Key People

  • Jeffrey W. Sherman

    Jeffrey W. Sherman, Chief Medical Officer

  • Jessica Hartung

    Jessica Hartung, Regional Medical Director

Operating MetricsView all

Pre-Clinical Phase Products

4
33.3%

Sep, 2021

Products

11
10.0%

FY, 2020

Phase 3b/4 Trials Products

3
50.0%

FY, 2019

LocationsView all

1 location detected

  • Dublin, D HQ

    Ireland

    70 St. Stephen’s Green Saint Kevin's

Horizon Therapeutics Financials

Summary Financials

Revenue (Q2, 2023)
$945.0M
Gross profit (Q2, 2023)
$725.0M
Net income (Q2, 2023)
$127.1M
Cash (Q2, 2023)
$2.5B
EBIT (Q2, 2023)
$142.8M

Footer menu